Medicare is set to undergo significant cost and coverage changes in 2026 and these updates could directly affect reimbursement, prescribing decisions and patient affordability. From drug pricing caps to premium adjustments, physicians should understand what’s coming to anticipate financial and clinical implications for their practices and patients.
One of the most striking changes: the average Part B premium is projected to rise from $185 to $206 per month in 2026, a 12% increase, double last year’s hike. This increase would more than offset the expected 2.7% Social Security adjustment, effectively reducing disposable income for many seniors.
While some Medicare Advantage and standalone Part D premiums may decrease slightly, insurers will have greater flexibility to raise Part D premiums (up to $50 per month). For physicians, this could mean more cost-sensitive patients, delayed care decisions and increased financial counseling conversations during clinical visits.
The Part B annual deductible is projected to rise 12% to $288, and the maximum deductible for Part D plans will increase as well. Although the Medicare Advantage in-network out-of-pocket maximum will drop slightly, the Part D annual drug cap will increase from $2,000 to $2,100.
Even small shifts can disproportionately impact patients on fixed incomes. Experts warn that higher deductibles, copays and coinsurance may lead to postponed procedures, skipped medications and reduced follow-up compliance, with potential downstream effects on outcomes.
Medicare officials will continue negotiating drug prices under Part D, with projected discounts of 38–79% on several widely used medications, including Eliquis, Xarelto, Januvia, Jardiance and Farxiga.
However, the number of standalone Part D plans will decline significantly (from 464 to 360), potentially limiting patient choice. Additionally, coverage shifts and formulary changes could increase costs for patients using specialty medications.
Physicians should anticipate possible formulary disruptions and more frequent prior authorization hurdles, especially in cardiology, endocrinology and oncology.
If federal budget disruptions continue, some Medicare administrative processes could be delayed, including claims processing and provider payments. Of particular concern is telehealth: certain pandemic-era telehealth flexibilities expired on October 1 and have not yet been renewed by Congress.
Restrictions could disproportionately affect rural, disabled and mobility-limited patients, potentially increasing missed visits, worsening chronic disease management and driving up long-term costs.
Nearly 69 million Americans rely on Medicare, and approximately half are enrolled in Medicare Advantage plans. With thousands of plans available nationwide and some insurers scaling back service areas patients may face complex decisions.
An estimated 70% of beneficiaries do not actively compare plan options during open enrollment. For clinicians, this creates an opportunity: proactive patient education now could reduce medication gaps, prevent cost-related nonadherence and protect continuity of care in 2026.
Read the full article here.